GDF-15 and/or troponin T for predicting kidney failure in heart surgery patients

Patent metadata

Field	Value
Publication number	US-11719710-B2
Application number	US-201916695713-A
Country	US
Kind code	B2
Filing date	Nov 26, 2019
Priority date	Dec 18, 2009
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.

First claim

The invention claimed is:

1. A method for treating a patient at risk of developing acute kidney injury (AKI) after coronary artery bypass graft (CABG) surgery, the method comprising:
identifying a patient as being at high risk of developing AKI after CABG surgery,
wherein the patient is identified by:
(a) determining the amount of a biomarker in a plasma or serum sample from the patient which has been taken within 1 week or 2 weeks before the patient undergoes CABG surgery, wherein the biomarker comprises GDF-15 and/or Troponin; and
(b) comparing the determined amount of the biomarker with a reference amount suitable for predicting whether a patient is at high risk of developing AKI after CABG surgery;
wherein the amount of GDF-15 is increased compared to a reference amount of GDF-15 and/or the amount of Troponin is increased compared to a reference amount of Troponin in a patient at high risk of developing AKI; and

administering a drug to the patient identified as being at high risk of developing AKI after CABG surgery.

2. The method of claim 1 , wherein the Troponin is Troponin T.

3. The method of claim 1 , wherein additionally the amount of a natriuretic peptide is determined and compared to a reference amount of the natriuretic peptide.

4. The method of claim 3 , wherein the natriuretic peptide is NT-proBNP.

5. The method of claim 1 , wherein the sample is taken within 6 hours, 12 hours or 24 hours before the surgical procedure.

6. The method of claim 1 , wherein the reference amount is an averaged median amount obtained from a group of patients before being subjected to surgery, and wherein the group of patients did not suffer from AKI after surgery.

7. The method of claim 1 , wherein the patient suffers from a cardiovascular disease.

8. The method of claim 7 , wherein the patient suffers from cardiovascular artherosclerosis.

9. The method of claim 1 , wherein the drug is erythropoietin.

Assignees

• Roche Diagnostics Operations Inc

Inventors

• Horsch Andrea
• Zdunek Dietmar
• Hess Georg

Classifications

• G01N33/74 Primary

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title

• C07K14/4716

  Muscle proteins, e.g. myosin, actin · CPC title

• G01N33/6863

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• G01N2333/4712

  Muscle proteins, e.g. myosin, actin, protein · CPC title